Cargando…
Access to medicines for treating people with cryptococcal meningitis
Cryptococcal meningitis accounts for one in five AIDS-related deaths globally. WHO guidelines strongly recommend a single high-dose of liposomal amphotericin B as part of preferred treatment, but this drug remains unaffordable in most low- and middle-income countries. A proactive approach is needed...
Autores principales: | Burry, Jessica, Casas, Carmen Perez, Ford, Nathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614173/ https://www.ncbi.nlm.nih.gov/pubmed/36037037 http://dx.doi.org/10.1093/cid/ciac689/6678599 |
Ejemplares similares
-
Treatment for HIV‐associated cryptococcal meningitis
por: Tenforde, Mark W, et al.
Publicado: (2018) -
Cryptococcal meningitis: A neglected NTD?
por: Molloy, Síle F., et al.
Publicado: (2017) -
Return of meningeal symptoms in a patient treated for cryptococcal meningitis
por: Huits, Ralph M. H. G., et al.
Publicado: (2007) -
Hearing Loss in Cryptococcal Meningitis Survivors
por: Lofgren, Sarah, et al.
Publicado: (2017) -
Molecular mechanisms of cryptococcal meningitis
por: Liu, Tong-Bao, et al.
Publicado: (2012)